HGFR and FGR2: Their Roles in Progression and Metastasis of Esophageal Cancer
Esophageal cancer (EC) is the sixth leading cause of malignancy-related death in the world. The disease is characterized by two types of histologies: esophageal squamous cell cancer (ESCC) and esophageal adenocarcinoma (EAC), which are the most common in the Western world. While alcohol has proven to lead to ESCC, it has not been associated with EAC. Progressive dysphagia (first with solids, followed by liquids) and rapid involuntary weight loss are the two most common symptoms, which make most patients seek medical attention. Most patients have a long period of symptoms before they seek care. At diagnosis, ~50% of the patients already have metastasis. The treatment of gastroesophageal cancers continues to pose significant clinical challenges for various defined reasons. The majority of patients fail intensive and toxic multimodality therapy for locoregional disease, and systemic chemotherapy for metastatic carcinoma gives short-term benefits only. Our understanding of the molecular pathology of gastroesophageal cancers has considerably increased during the recent years, leading to the development of novel targeted therapeutic agents that have proven to be promising in improving the patients’ survival with minimal adverse events. Receptor tyrosine kinases (RTKs) play pivotal role(s) in the formation, maintenance, growth, and differentiation of the malignant cells encompassing both histological types of EC. Malignancies treated with chemotherapy/radiation therapy face the challenge of developing resistance and increasing the aggressive nature of cancerous cells leading to undesirable recurrence. In peer-reviewed literature, an array of RTKs have been described in ESCC, and more recently, they are being assessed for their therapeutic utility. Notably, structures of hepatocyte growth factor receptor (HGFR) and fibroblast growth factors receptor 2 (FGR2) are two of the many prominent RTKs studies thus far. In this chapter, we thoroughly discuss the clinical characteristics of the disease and structure-functional aspects of various RTKs with focus on HGFR and FGR2 as it relates to the translational and clinical outcomes of EC.
KeywordsEsophageal cancer Receptor tyrosine kinases Hepatocyte growth factor receptor Fibroblast growth factors receptor 2 Metastasis
Conflict of Interest
None of the authors has any potential financial or commercial conflict of interest associated with this research manuscript (chapter).
- 47.Centers for Disease Control and Prevention. Global Cancer Statistics. Available online: http://www.cdc.gov/cancer/international/statistics.html. Accessed 4 Apr 2018
- 48.National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER Fact Sheets: Esophageal Cancer. Available online: http://seer.cancer.gov/statfacts/ html/esoph.html. Accessed 4 Apr 2018
- 52.Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M et al (2014) Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol 15(9):1007–1018CrossRefGoogle Scholar
- 53.Cunningham D, Bang Y-J, Tabernero J, Shah MA, Lordick F, Hack SP (2013) MetGastric: a randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction. American Society of Clinical OncologyGoogle Scholar
- 54.Shah MA, Bang Y-J, Lordick F, Tabernero J, Chen M, Hack SP, et al (2015) METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). American Society of Clinical OncologyGoogle Scholar
- 55.Inokuchi M, Fujimori Y, Otsuki S, Sato Y, Nakagawa M, Kojima K (2015) Therapeutic targeting of fibroblast growth factor receptors in gastric cancer. Gastroenterol Res Pract 2015Google Scholar
- 57.Bang Y-J, Van Cutsem E, Mansoor W, Petty RD, Chao Y, Cunningham D, et al (2015) A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study. American Society of Clinical OncologyGoogle Scholar
- 58.Saka H, Kitagawa C, Kogure Y, Takahashi Y, Fujikawa K, Sagawa T, Iwasa S, Takahashi N, Fukao T, Tchinou C, Landers D, Yamada Y (2017) Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a phase I study. Investig New Drugs 35:451–462CrossRefGoogle Scholar
- 62.Horner M, Ries L, Krapcho M et al (2009) SEER cancer statistics review, 1975–2006, National Cancer Institute. U.S. Department of Health and Human Services, National Institutes of Health, BethesdaGoogle Scholar
- 63.Howlader N, Noone A, Krapcho M et al (2011) SEER cancer statistics review, 1975–2008, National Cancer Institute. U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, p 19Google Scholar
- 66.Davey Smith G, Neaton JD, Wentworth D, Stamler R, Stamler J (1998) Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for the MRFIT. MRFIT research group. Multiple risk factor intervention trial. Lancet 351:934–939CrossRefGoogle Scholar